| 0.922 -0.078 (-7.8%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.81 | 1-year : | 2.11 |
| Resists | First : | 1.54 | Second : | 1.81 |
| Pivot price | 0.59  |
|||
| Supports | First : | 0.76 | Second : | 0.28 |
| MAs | MA(5) : | 0.89  |
MA(20) : | 0.52 |
| MA(100) : | 0.44 |
MA(250) : | 2.25 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 49.8 |
D(3) : | 45.6 |
| RSI | RSI(14): 66.8 |
|||
| 52-week | High : | 7.28 | Low : | 0.25 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ TBIO ] has closed below upper band by 16.0%. Bollinger Bands are 261.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1 - 1.01 | 1.01 - 1.01 |
| Low: | 0.89 - 0.89 | 0.89 - 0.89 |
| Close: | 0.99 - 1 | 1 - 1.01 |
Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.
Tue, 18 Mar 2025
$21M Investment Powers Telesis Bio's Game-Changing Overnight DNA Synthesis Technology - Stock Titan
Tue, 18 Mar 2025
TBIO - TRANSLATE BIO, INC. Latest Stock News & Market Updates - Stock Titan
Thu, 26 Sep 2024
Why Telesis Bio Shares Are Trading Higher By Around 110%; Here Are 20 Stocks Moving Premarket - MSN
Thu, 26 Sep 2024
What's Going On With Telesis Bio Shares Thursday? - TradingView
Thu, 26 Sep 2024
Why Telesis Bio Shares Are Trading Higher By Around 110%; Here Are 20 Stocks Moving Premarket - TradingView
Wed, 25 Sep 2024
Telesis Bio Stock Is Soaring Wednesday: What's Going On? - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 4.6 (%) |
| Held by Institutions | 30.5 (%) |
| Shares Short | 30 (K) |
| Shares Short P.Month | 25 (K) |
| EPS | -30.43 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -15.36 |
| Profit Margin | -267.5 % |
| Operating Margin | -328.5 % |
| Return on Assets (ttm) | -30.2 % |
| Return on Equity (ttm) | -179 % |
| Qtrly Rev. Growth | -61.8 % |
| Gross Profit (p.s.) | 4.48 |
| Sales Per Share | 9.56 |
| EBITDA (p.s.) | -16.12 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -23 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -0.04 |
| PEG Ratio | 0 |
| Price to Book value | -0.07 |
| Price to Sales | 0.1 |
| Price to Cash Flow | -0.08 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|